Study of lipid profile in polycystic ovarian syndrome: a case control study in tertiary care hospital
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20233634Keywords:
Dyslipidemia, Polycystic ovarian syndrome, Cholesterol, TG, LDL, HDLAbstract
Background: Polycystic ovarian syndrome (PCOS) is one of the most common causes of endocrine dysfunction in women of reproductive age. Dyslipidaemia plays an important role in the development of PCOS. Lipid abnormalities which include elevated low-density lipoprotein and triglyceride levels and reduced high-density lipoprotein levels are often found in women with PCOS and thus they are associated with long-term risk of coronary heart disease. The study aims to estimate lipid profile levels in patients with polycystic ovarian syndrome (PCOS) taken as cases and normal healthy subjects taken as controls.
Methods: This is a case control study conducted in the Department of Biochemistry in collaboration with Department of Obstetrics and Gynaecology, RIMS, Imphal. Fasting blood samples were collected from cases and controls and lipid parameters were estimated. Forty-five cases of PCOS patients in the age group of 18-44 years diagnosed according to Rotterdam criteria and forty-five age-matched healthy women with regular menstrual cycle taken as controls were recruited.
Results: The mean±SD of age in cases was 26.38±4.85 years and control was 28.23±3.99 years. However, the difference was found to be statistically insignificant. The majority of cases were from urban areas which comprised of 62% and only 55.6% were from rural areas. The mean±SD for cholesterol, TG, LDL were 203.40±54.20 mg/dl, 163.26±69.49 mg/dl, 132.82±50.39 mg/dl respectively and was higher in cases compared to controls and the difference was statistically significant. However, the mean±SD of HDL in cases 24.81±2.31mg/dl was lower as compared to controls and the difference was statistically significant with p<0.05.
Conclusions: PCOS is found to be associated with atherogenic lipid profile. Thus, it may be suggested that dietary control and improvement of living style to control dyslipidaemia should be taken up early in PCOS to prevent development of cardiovascular disease.
Metrics
References
Dasgupta S, Dutta J, Annamaneni S, Kudugunti N, Battni MR. Association of Vitamin D receptor gene polymorphisms with polycystic ovary syndrome among Indian women. Indian J Med Res. 2015; 142(3):276-85.
Conway G, Dewaily D, Diamanti -Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):1-29.
Sirmans SM, Pate KA. Endocrinology, diagnosis and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6(1):1-13.
Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes Spectr. 2015;28(2):116-20.
Teede H, Deeks A, Moran L. Polycystic ovary syndrome; A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8(41):1-10.
Gupta M, Singh D, Toppo M, Priya A, Sethia S, Gupta P. A cross sectional study of polycystic ovarian syndrome among young women in Bhopal, Central India. Int J Community Med Public Health. 2018; 5(1):95-100.
Qi L, Yuan-Jie X, Li HQ, Mengxia Z, Zhong CM. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2019;58(4):447-53.
Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607-13.
Saniana K, Vaibhave U, Rajesh KJ. Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective. 2021;17(10):2706-33.
Sonya JE, Alice HL, Anastassios GP. Genetic and environmental influences on factors associated with cardiovascular disease and the metabolic syndrome. J Lipid Res. 2009;50(9):1917-26.
Cristian-Ioan IU, Nicolae CO, Dan MI. Lipid parameters in patients with polycystic ovary syndrome. App Med Inform. 2012;31(4):27-32.
Talbott EO, Guzick DS, Sutton-tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, et al. Evidence for Association Between Polycystic ovary syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women. Arterioscler Thromb Vasc Biol. 2000;20(11):2414-21.
Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Rev Dis Primers. 2016;2:16-57.
Laven JS, Legro RS. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
Bashir R, Sideeq K. Prevalence of polycystic ovarian syndrome in women of different age groups in Hazratbal area of Srinagar by ultrasonographic evaluation-hospital data based study. Int J App Res. 2020;6(6):292-5.
Bharati RV, Swetha S, Neeraja J, Madhavica JV, Moorthy JD, Rekha SN, et al. An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertil Soc J. 2017;22(1):313-5.
Yadav S, Tarware R. Waist hip ratio: An anatomical predictive marker of risk of PCOS. Int J Reprod Contracept Obstet Gynecol. 2019;8 (4):1630-2.
Wu CH, Chiu LT, Chang YJ. Hypertension Risk in Young Women with Polycystic Ovary Syndrome: A nationwide Population-Based Cohort Study. Front Med. 2020;7(574):1-9.
Manjunatha S, Amruta SB, Shaktiprasad H, Veena HC. Effect of PCOS on lipid Profile. Sch J App Med Sci. 2014;2(3):1153-5.
Lambrinoudaki I, Christodoulakos G, Rizos D. Endogenous sex hormones and risk factors for Atherosclerosis in health Greek postmenopausal women. Eur J Endocrinol. 2016;154(6):907.
Buccola JM, Reynolds EE. Polycystic ovary syndrome; a review for primary providers. Prim Care. 2003;30(4):697-710.
Cinar N, Kizilarslanoglu MC, Harmanci A. Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Human Reprod. 2011;26: 3339-45.
Downloads
Published
How to Cite
Issue
Section
